Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 12 mechanisms across 26 industry trials with a known mechanism of action.

See full pipeline →

Transferrin

1 trials 1 active 1 sponsor

Sodium-Glucose Cotransporter 2 Inhibitor

8 trials 2 sponsors

SGLT2

5 trials 1 sponsor

Vasopressin V2 Receptor Antagonist

3 trials 2 sponsors

Soluble Guanylate Cyclase Stimulator

2 trials 1 sponsor

ACE

1 trials 1 sponsor

Prostaglandin Analog

1 trials 1 sponsor

Glucose-dependent Insulinotropic Polypeptide Receptor Agonist

1 trials 1 sponsor

Factor Xa Inhibitor

1 trials 1 sponsor

Aldosterone Antagonist

1 trials 1 sponsor

Dihydropyridine Calcium Channel Blocker

1 trials 1 sponsor

Cardiac Myosin Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

420 industry-sponsored trials across 157 sponsors

View full landscape →

Showing 45 of 45 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
AstraZeneca	Acalabrutinib	—	RECRUITING	2030-08-16	NCT06651970
Sarfez Pharmaceuticals, Inc.	Extended Release Torsemide Tablets	—	COMPLETED	2025-12-30	NCT06995144
Novartis	Sacubitril/valsartan	—	COMPLETED	2025-03-16	NCT04023227
Bayer	Vericiguat (Verquvo, BAY1021189)	—	COMPLETED	2024-09-19	NCT05658458
Novartis	sacubitril/valsatran	—	COMPLETED	2022-03-23	NCT03300427
Vifor (International) Inc.	ferric carboxymaltose	—	COMPLETED	2020-07-21	NCT02937454
Novartis	LCZ696	—	COMPLETED	2019-11-25	NCT02768298
AstraZeneca	Saxagliptin	—	COMPLETED	2019-08-23	NCT02917031
Amgen	Ivabradine	—	COMPLETED	2019-04-19	NCT03456856
Abbott Medical Devices	Warfarin	—	COMPLETED	2019-02-21	NCT02836652
Novartis	LCZ696 (sacubitril/valsartan)	—	COMPLETED	2018-12-13	NCT02874794
Novartis	LCZ696 (sacubitril/valsartan)	—	COMPLETED	2018-10-22	NCT02887183
Novartis	sacubitril/valsartan (LCZ696)	—	COMPLETED	2018-06-29	NCT02554890
Novartis	sacubitril/valsartan (LCZ696)	—	COMPLETED	2018-03-19	NCT02970669
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.	Shenfu Zhusheye	—	COMPLETED	2017-03-24	NCT02135835
Biotronik SE & Co. KG	—	—	COMPLETED	2017-03	NCT00643188
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2015-12	NCT01434615
Biotronik SE & Co. KG	—	—	COMPLETED	2015-06	NCT01711281
ResMed	—	—	COMPLETED	2015-04	NCT01164592
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2014-11	NCT00769457
Chong Kun Dang Pharmaceutical	Candemore tablet	—	COMPLETED	2014-10	NCT01682564
Otsuka Pharmaceutical Co., Ltd.	Tolvaptan	Vasopressin V2 Receptor Antagonist [EPC]	COMPLETED	2014-03	NCT01439009
GE Healthcare	AdreView (Iobenguane I 123 Injection)	—	COMPLETED	2014-02	NCT01936649
Biotronik Japan, Inc.	—	—	COMPLETED	2014-02	NCT01221649
Vifor Pharma	Ferinject (ferric carboxymaltose)	—	COMPLETED	2014-02	NCT01453608
JW Pharmaceutical	pitavastatin	—	COMPLETED	2013-05	NCT00701285
Novartis	vildagliptin	—	COMPLETED	2012-08	NCT00894868
Merck KGaA, Darmstadt, Germany	Low Dose Bisoprolol	—	COMPLETED	2012-08	NCT01074307
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2012-07	NCT00821938
Abbott Medical Devices	—	—	COMPLETED	2012-04	NCT01295840
Biotronik SE & Co. KG	—	—	COMPLETED	2012-01	NCT00711360
Abbott Medical Devices	—	—	COMPLETED	2011-04	NCT00964938
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2011-03	NCT00847288
Medtronic Italia	—	—	COMPLETED	2010-10	NCT01109641
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2010-07	NCT01104558
Boston Scientific Corporation	—	—	COMPLETED	2010-07	NCT00677014
Novartis	ACEI/ARB	—	TERMINATED	2023-06-08	NCT04491136
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	TERMINATED	2018-12-26	NCT03026088
Korea Otsuka Pharmaceutical Co., Ltd.	Tolvaptan	Vasopressin V2 Receptor Antagonist [EPC]	TERMINATED	2017-01	NCT02352285
Ferrer Internacional S.A.	torasemide-PR	—	TERMINATED	2012-10	NCT01549158
Medtronic Cardiac Rhythm and Heart Failure	—	—	TERMINATED	2012-03	NCT00839566
LivaNova	—	—	TERMINATED	2011-09	NCT01170624
Sarfez Pharmaceuticals, Inc.	torsemide	—	WITHDRAWN	2025-03-25	NCT06708611
Ascension Health	Lisinopril	ACE	WITHDRAWN	2018-12-15	NCT03392740
Abbott Medical Devices	—	—	WITHDRAWN	2016-01	NCT02421549

Showing 100 of 108 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Novo Nordisk	Ziltivekimab	—	RECRUITING	2026-10-01	NCT06200207
AstraZeneca	balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg	—	RECRUITING	2027-06-11	NCT06307652
HELP Therapeutics Co., Ltd.	HiCM-188 therapy	—	RECRUITING	2027-06-30	NCT07496372
Novo Nordisk	Ziltivekimab	—	RECRUITING	2027-07-02	NCT05636176
Reprieve Cardiovascular, Inc	furosemide infusion	—	RECRUITING	2027-08	NCT06898515
Cytokinetics	Omecamtiv Mecarbil (OM)	—	RECRUITING	2027-09	NCT06736574
Pharmacosmos A/S	Ferric Derisomaltose	Transferrin	RECRUITING	2027-12-01	NCT06929806
Boehringer Ingelheim	vicadrostat	—	RECRUITING	2028-05-22	NCT06424288
Amgen	Maridebart cafraglutide	—	RECRUITING	2028-06-30	NCT07037459
Boehringer Ingelheim	vicadrostat	—	RECRUITING	2029-02-04	NCT06935370
Bayer	Finerenone (Kerendia, BAY94-8862)	—	RECRUITING	2029-11-30	NCT07188805
AstraZeneca	Baxdrostat and dapagliflozin	—	RECRUITING	2029-12-17	NCT06677060
Merck	Vericiguat tablet	—	RECRUITING	2032-04-15	NCT05714085
Pulnovo Medical (Wuxi) Co., Ltd.	Guideline-directed medical therapy (GDMT) for heart failure	—	RECRUITING	2025-08	NCT05824923
Novo Nordisk	NNC0487-0111	—	NOT YET RECRUITING	2029-07-23	NCT07567001
Biopeutics Co., Ltd	Alprostadil	Prostaglandin Analog [EPC]	NOT YET RECRUITING	2029-11	NCT00610051
Bayer	Finerenone (Kerendia, BAY94-8862)	—	NOT YET RECRUITING	2030-12-30	NCT07192952
BioCardia, Inc.	Autologous cell therapy	—	COMPLETED	2025-02	NCT02438306
Merck	Vericiguat	Soluble Guanylate Cyclase Stimulator [EPC]	COMPLETED	2024-11-20	NCT05093933
Zensun Sci. & Tech. Co., Ltd.	Neucardin	—	COMPLETED	2024-08-30	NCT05949801
Novartis	sacubitril/valsartan	—	COMPLETED	2024-08-14	NCT06149104
Eli Lilly	Tirzepatide	Glucose-dependent Insulinotropic Polypeptide Receptor Agonist [EPC]	COMPLETED	2024-07-02	NCT04847557
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2024-05-15	NCT04435626
AstraZeneca	AZD4831	—	COMPLETED	2024-03-27	NCT04986202
Novartis	sacubitril/valsartan	—	COMPLETED	2023-12-29	NCT03785405
AstraZeneca	Dapagliflozin	SGLT2	COMPLETED	2023-07-05	NCT04564742
American Regent, Inc.	Ferric Carboxymaltose	—	COMPLETED	2023-02-02	NCT03037931
Novartis	sacubitril/valsartan	—	COMPLETED	2022-12-14	NCT03988634
Novartis	LCZ696	—	COMPLETED	2022-05-16	NCT02884206
Zensun Sci. & Tech. Co., Ltd.	Recombinant human Neuregulin for injection	—	COMPLETED	2022-04-12	NCT04468529
AstraZeneca	Dapagliflozin	SGLT2	COMPLETED	2022-03-27	NCT03619213
Novartis	LCZ696	—	COMPLETED	2022-01-03	NCT02678312
Johnson & Johnson	Canagliflozin 100 mg	—	COMPLETED	2021-11-09	NCT04252287
Otsuka Pharmaceutical Co., Ltd.	Tolvaptan	Vasopressin V2 Receptor Antagonist [EPC]	COMPLETED	2021-07-11	NCT03255226
scPharmaceuticals, Inc.	—	—	COMPLETED	2021-06-24	NCT03458325
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2021-05-28	NCT04157751
Novartis	LCZ696	—	COMPLETED	2021-05-25	NCT03917459
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2021-04-26	NCT03057951
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2020-12-30	NCT03884504
Cytokinetics	Omecamtiv Mecarbil	—	COMPLETED	2020-09-14	NCT02929329
Otsuka Pharmaceutical Co., Ltd.	OPC-61815	—	COMPLETED	2020-07-21	NCT03772041
AstraZeneca	Dapagliflozin	SGLT2	COMPLETED	2020-07-09	NCT03877224
Otsuka Pharmaceutical Co., Ltd.	OPC-61815 injection	—	COMPLETED	2020-06-30	NCT03962101
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2020-05-21	NCT03332212
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2020-05-01	NCT03057977
AstraZeneca	Dapagliflozin	SGLT2	COMPLETED	2020-03-07	NCT03877237
Mesoblast, Inc.	Rexlemestrocel-L	—	COMPLETED	2020-01-30	NCT02032004
Novartis	sacubitril/valsartan	—	COMPLETED	2019-10-28	NCT03066804
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2019-10-04	NCT03448406
Boehringer Ingelheim	Empagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	COMPLETED	2019-09-30	NCT03448419
Dr. F. Köhler Chemie GmbH	Custodiol-N	—	COMPLETED	2019-09-02	NCT02869022
AstraZeneca	Dapagliflozin	SGLT2	COMPLETED	2019-07-17	NCT03036124
Merck	Vericiguat	Soluble Guanylate Cyclase Stimulator [EPC]	COMPLETED	2019-06-18	NCT02861534
Novartis	LCZ696	—	COMPLETED	2019-06-07	NCT01920711
Novartis	LCZ696	—	COMPLETED	2019-02-08	NCT02468232
Johnson & Johnson	Rivaroxaban	Factor Xa Inhibitor [EPC]	COMPLETED	2018-04-19	NCT01877915
Novartis	LCZ696 (Sacubitril/Valsartan)	—	COMPLETED	2018-04-11	NCT02900378
Johnson & Johnson	Rivaroxaban, 10 mg	—	COMPLETED	2018-03-06	NCT02111564
Novartis	LCZ696	—	COMPLETED	2017-12-28	NCT02226120
Celyad Oncology SA	Injection of C3BS-CQR-1	—	COMPLETED	2017-08	NCT01768702
Novartis	RLX030	—	COMPLETED	2017-01-23	NCT01870778
scPharmaceuticals, Inc.	—	—	COMPLETED	2016-11	NCT02804282
Cardiovascular Clinical Sciences Inc	Tolvaptan or Samsca	—	COMPLETED	2016-07	NCT01584557
Vifor Pharma	Ferinject (ferric carboxymaltose)	—	COMPLETED	2016-05	NCT01394562
Cardiorentis	Ularitide	—	COMPLETED	2015-11	NCT01661634
scPharmaceuticals, Inc.	Fursemide Injection Solution for subcutaneous administration (80 mg)	—	COMPLETED	2015-10	NCT02329834
Novartis	Enalapril	—	COMPLETED	2015-10	NCT00853658
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Eplerenone	Aldosterone Antagonist [EPC]	COMPLETED	2015-09	NCT01115855
Abbott Medical Devices	—	—	COMPLETED	2015-04	NCT01786993
Abbott Medical Devices	—	—	COMPLETED	2014-08	NCT01362725
LoneStar Heart, Inc.	Standard medical therapy	—	COMPLETED	2014-04	NCT01311791
LivaNova	—	—	COMPLETED	2013-06	NCT02167789
Novartis	Aliskiren	—	COMPLETED	2012-08	NCT00894387
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2012-07	NCT00887237
LivaNova	—	—	COMPLETED	2012-03	NCT01193634
Lee's Pharmaceutical Limited	Levocarnitine Injection	—	COMPLETED	2012-03	NCT01580553
The Medicines Company	Clevidipine	Dihydropyridine Calcium Channel Blocker [EPC]	COMPLETED	2012-02	NCT00803634
LivaNova	—	—	COMPLETED	2011-06	NCT01169272
Celyad Oncology SA	C-Cure	—	COMPLETED	2010-07	NCT00810238
Biogen	tonapofylline	—	COMPLETED	2009-10-30	NCT00709865
Takeda	Candesartan	—	COMPLETED	2008-12	NCT00775840
Lexicon Pharmaceuticals	Sotagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	TERMINATED	2020-07-08	NCT03315143
Lexicon Pharmaceuticals	Sotagliflozin	Sodium-Glucose Cotransporter 2 Inhibitor [EPC]	TERMINATED	2020-06-05	NCT03521934
United Therapeutics	Oral treprostinil	—	TERMINATED	2019-12-03	NCT03037580
Novartis	LCZ696	—	TERMINATED	2019-11-19	NCT03909295
GE Healthcare	Iobenguane I -123 Injection	—	TERMINATED	2018-05-04	NCT02656329
Zensun Sci. & Tech. Co., Ltd.	rhNRG-1	—	TERMINATED	2017-08	NCT01541202
CardioKinetix, Inc	—	—	TERMINATED	2017-06	NCT01614652
Novartis	Serelaxin	—	TERMINATED	2017-03-27	NCT02007720
Novartis	Serelaxin	—	TERMINATED	2017-03-26	NCT02064868
BioControl Medical	—	—	TERMINATED	2015-12	NCT01303718
Medtronic Endovascular	—	—	TERMINATED	2015-03	NCT01844037
Boston Scientific Corporation	—	—	TERMINATED	2014-04	NCT01872234
Eurofarma Laboratorios S.A.	Diurisa®	—	TERMINATED	2013-03-01	NCT01210365
Biotronik, Inc.	—	—	TERMINATED	2013-03	NCT00683696
CardioKinetix, Inc	—	—	TERMINATED	2013-01	NCT01286116
Zensun Sci. & Tech. Co., Ltd.	rhNRG-1	—	TERMINATED	2012-06	NCT01439789
Zensun Sci. & Tech. Co., Ltd.	rhNRG-1	—	TERMINATED	2012-06	NCT01131637
Zensun Sci. & Tech. Co., Ltd.	rhNRG-1	—	TERMINATED	2012-06	NCT01439893
Zensun Sci. & Tech. Co., Ltd.	rhNRG-1	—	TERMINATED	2011-01	NCT01214096

Showing 100 of 167 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-9057 injection set	—	RECRUITING	2026-07	NCT07318103
Bristol-Myers Squibb	BMS-986435	—	RECRUITING	2026-07-03	NCT06122779
Sinotau Pharmaceutical Group	Fasting XTR003/¹⁸F-FDG PET myocardial metabolic imaging	—	RECRUITING	2026-08	NCT07443696
Cytokinetics	CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)	—	RECRUITING	2026-09	NCT06793371
Innovent Biologics (Suzhou) Co. Ltd.	IBI362	—	RECRUITING	2026-09-24	NCT06862908
Tectonic Therapeutic	TX000045- Dose A	—	RECRUITING	2026-10-09	NCT06616974
Corteria Pharmaceuticals	COR-1167	—	RECRUITING	2026-12	NCT06815471
Shandong Suncadia Medicine Co., Ltd.	HRS-7535 tablet	—	RECRUITING	2026-12	NCT06820099
Iperboreal Pharma Srl	PolyCore (Polydextrin, L-Carnitine, D-xylitol)	—	RECRUITING	2026-12	NCT03994874
Tasly Pharmaceutical Group Co., Ltd	Mesenchymal stem cells(HucMSCs)	—	RECRUITING	2026-12-31	NCT07265349
Shandong Suncadia Medicine Co., Ltd.	HRS-1893 Tablet	—	RECRUITING	2027-03	NCT07269717
Novo Nordisk	CDR132L	—	RECRUITING	2027-05-16	NCT06979375
Novo Nordisk	CDR132L	—	RECRUITING	2027-05-16	NCT06979362
Pfizer	Low Dose PF-07328948	—	RECRUITING	2027-11-16	NCT06991257
Salubris Biotherapeutics Inc	JK07	—	RECRUITING	2025-12-31	NCT06369298
Sardocor Corp.	SRD-001	—	RECRUITING	2025-12-31	NCT04703842
AskBio Inc	AB-1002	—	ACTIVE NOT RECRUITING	2026-10-31	NCT05598333
HELP Therapeutics Co., Ltd.	HiCM-188 therapy	—	ACTIVE NOT RECRUITING	2026-11-10	NCT06340048
BioCardia, Inc.	—	—	ACTIVE NOT RECRUITING	2026-12	NCT05925608
Akros Pharma Inc.	JTT-861 Capsules	—	ACTIVE NOT RECRUITING	2026-05	NCT06017609
Implicit Bioscience	Atibuclimab (IC14)	—	ACTIVE NOT RECRUITING	2026-04-30	NCT06556810
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS9531	—	ACTIVE NOT RECRUITING	2026-01	NCT06391710
Heartseed Inc.	HS-001 CS	—	ACTIVE NOT RECRUITING	2025-07-31	NCT04945018
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)	18F-metaFluorobenzylguanidine	—	NOT YET RECRUITING	2026-10-30	NCT06965621
Tasly Pharmaceutical Group Co., Ltd	Low dose Jia Shen Tablet	—	NOT YET RECRUITING	2026-12-31	NCT06669169
HELP Therapeutics Co., Ltd.	low dose CABG+iPSC-CMs	—	NOT YET RECRUITING	2027-12	NCT06866600
Heartseed Inc.	—	—	NOT YET RECRUITING	2028-01-01	NCT07347197
AnaCardio AB	AC01	—	NOT YET RECRUITING	2028-04-22	NCT07584967
HELP Therapeutics Co., Ltd.	HiCM-188 Chitosan Patch	—	NOT YET RECRUITING	2028-10-20	NCT07471698
AstraZeneca	AZD5462	—	COMPLETED	2026-02-10	NCT06299826
Sarfez Pharmaceuticals, Inc.	Extended release torsemide	—	COMPLETED	2025-11-17	NCT06206512
Cardurion Pharmaceuticals, Inc.	Tovinontrine (CRD-750)	—	COMPLETED	2025-10-10	NCT06215911
Cardurion Pharmaceuticals, Inc.	Tovinontrine (CRD-750	—	COMPLETED	2025-09-02	NCT06215586
AstraZeneca	AZD3427	—	COMPLETED	2025-07-15	NCT05737940
Regeneron	REGN5381	—	COMPLETED	2025-06-02	NCT05353166
Tasly Pharmaceutical Group Co., Ltd	Qishen Yiqi dripping pills 4 bags/time	—	COMPLETED	2024-12-19	NCT04944706
Tasly Pharmaceutical Group Co., Ltd	Low dose QiShen YiQi Dripping Pills 3 bags	—	COMPLETED	2024-11-27	NCT04983043
River 2 Renal Corp.	R2R01	—	COMPLETED	2024-11-04	NCT06264310
Cardior Pharmaceuticals GmbH	CDR132L	—	COMPLETED	2024-09-26	NCT05350969
Imbria Pharmaceuticals, Inc.	IMB-1018972	—	COMPLETED	2024-08-06	NCT04826159
Bayer	Vericiguat (BAY1021189) 5 mg	—	COMPLETED	2024-07-29	NCT06195930
Rivus Pharmaceuticals, Inc.	HU6	—	COMPLETED	2024-05-24	NCT05284617
HELP Therapeutics Co., Ltd.	hPSC-CM Therapy	—	COMPLETED	2024-04-30	NCT03763136
Bristol-Myers Squibb	mavacamten	Cardiac Myosin Inhibitor [EPC]	COMPLETED	2024-02-26	NCT04766892
AstraZeneca	AZD9977	—	COMPLETED	2023-09-22	NCT04595370
Tenax Therapeutics, Inc.	Levosimendan	—	COMPLETED	2023-04-25	NCT03624010
Berlin Cures GmbH	BC 007	—	COMPLETED	2022-12-06	NCT04192214
Ionis Pharmaceuticals, Inc.	IONIS-AGT-LRx	—	COMPLETED	2022-10-19	NCT04836182
AstraZeneca	Verinurad	—	COMPLETED	2022-04-29	NCT04327024
Shanghai Hongyitang Biopharmaceutical Technology Co. Ltd.	TSG-01	—	COMPLETED	2022-04-22	NCT04515290
scPharmaceuticals, Inc.	—	—	COMPLETED	2022-04-18	NCT04593823
Bristol-Myers Squibb	BMS-986259	—	COMPLETED	2021-07-19	NCT04318093
AstraZeneca	AZD8601	—	COMPLETED	2021-06-30	NCT03370887
SQ Innovation, Inc.	Furosemide Injection Solution for subcutaneous administration (80 mg)	—	COMPLETED	2021-06-12	NCT04384653
Bayer	BAY 1753011	—	COMPLETED	2021-04-16	NCT03901729
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2021-03-12	NCT03153111
Tenax Therapeutics, Inc.	Levosimendan	—	COMPLETED	2020-04-07	NCT03541603
Intra-Cellular Therapies, Inc.	ITI-214	—	COMPLETED	2020-03-16	NCT03387215
Bristol-Myers Squibb	BMS-986231	—	COMPLETED	2019-12-11	NCT03730961
Bayer	Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets	—	COMPLETED	2019-10-15	NCT03547583
Akebia Therapeutics	IW-1973	—	COMPLETED	2019-08-19	NCT03254485
Bristol-Myers Squibb	HNO Donor	—	COMPLETED	2019-06-23	NCT03016325
Bristol-Myers Squibb	HNO Donor	—	COMPLETED	2019-05-10	NCT03357731
Novartis	CLR325	—	COMPLETED	2019-01-14	NCT02696967
Tau-MEDICAL Co., Ltd.	—	—	COMPLETED	2018-11-17	NCT03453853
Cardiora Pty. Ltd.	CRD-102	—	COMPLETED	2018-10-10	NCT03217331
Windtree Therapeutics	Istaroxime	—	COMPLETED	2018-08-14	NCT02617446
Bayer	Neladenoson bialanate (BAY1067197)	—	COMPLETED	2018-05-23	NCT03098979
Bayer	Neladenoson bialanate (BAY1067197)	—	COMPLETED	2018-03-28	NCT02992288
PhaseBio Pharmaceuticals Inc.	PB1046 Injection	—	COMPLETED	2017-12-06	NCT02808585
Stealth BioTherapeutics Inc.	elamipretide	—	COMPLETED	2017-11-27	NCT02914665
Stealth BioTherapeutics Inc.	4 mg elamipretide	—	COMPLETED	2017-09	NCT02788747
GSK	GSK2798745	—	COMPLETED	2017-08-21	NCT02497937
CardioCell LLC	Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)	—	COMPLETED	2017-05-11	NCT02467387
Stealth BioTherapeutics Inc.	elamipretide	—	COMPLETED	2017-05-04	NCT02814097
scPharmaceuticals, Inc.	—	—	COMPLETED	2016-08	NCT02804035
Capricor Inc.	Cenderitide	—	COMPLETED	2016-03-31	NCT02603614
Trevena Inc.	TRV027 Dose #1	—	COMPLETED	2016-03	NCT01966601
Bayer	BAY1142524	—	COMPLETED	2016-01	NCT02452515
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2015-10	NCT01213251
Novartis	RLX030 (serelaxin)	—	COMPLETED	2015-09	NCT01982292
Bayer	Vericiguat (BAY1021189) (1.25 mg)	—	COMPLETED	2015-08-18	NCT01951638
Cytokinetics	Omecamtiv Mecarbil Matrix F1 Formulation	—	COMPLETED	2015-07-22	NCT01786512
scPharmaceuticals, Inc.	Furosemide injection solution for subcutaneous administration (80 mg)	—	COMPLETED	2015-06	NCT02350725
Bristol-Myers Squibb	CXL-1427	—	COMPLETED	2015-05-31	NCT02157506
Bayer	Vericiguat (BAY1021189) (1.25 mg)	—	COMPLETED	2015-05-14	NCT01951625
Capricor Inc.	Cenderitide	—	COMPLETED	2015-04-02	NCT02359227
Celladon Corporation	—	—	COMPLETED	2015-02	NCT01643330
Bayer	BAY1067197 (10 mg)	—	COMPLETED	2015-01-29	NCT02040233
Bayer	BAY94-8862	—	COMPLETED	2015-01-23	NCT01955694
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2014-11-11	NCT01807221
Bayer	BAY1067197 (treatment 2)	—	COMPLETED	2014-09-09	NCT01945606
Novartis	Serelaxin	—	COMPLETED	2014-08	NCT02002702
Cyberonics, Inc.	—	—	COMPLETED	2014-04	NCT01823887
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2014-01	NCT01112579
Cytokinetics	Omecamtiv mecarbil	—	COMPLETED	2013-04	NCT01300013
Novartis	RLX030	—	COMPLETED	2013-01	NCT01543854
Zensun Sci. & Tech. Co., Ltd.	rhNRG-1 Dose 1	—	COMPLETED	2012-12	NCT01251406
Novartis	RLX030	—	COMPLETED	2012-12	NCT01546532
GE Healthcare	GE-145	—	COMPLETED	2012-12	NCT01252810

Showing 100 of 100 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Vasa Therapeutics	VS-041	—	RECRUITING	2026-06	NCT07219511
Tasly Pharmaceutical Group Co., Ltd	Jia Shen Tablet	—	RECRUITING	2026-06-30	NCT06348498
Novo Nordisk	NNC0537-1482	—	RECRUITING	2027-01-15	NCT07218627
Secretome Therapeutics	STM01	—	RECRUITING	2025-12-15	NCT06560762
Sardocor Corp.	AAV1/SERCA2a	—	RECRUITING	2025-08	NCT06061549
Beijing Suncadia Pharmaceuticals Co., Ltd	SHR-6934 injection	—	ACTIVE NOT RECRUITING	2026-08	NCT06700083
AskBio Inc	3 x 10e13vg AB-1002	—	ACTIVE NOT RECRUITING	2024-08-20	NCT04179643
Beijing Suncadia Pharmaceuticals Co., Ltd	SHR-4658 Injection.	—	NOT YET RECRUITING	2026-06	NCT07230145
Chengdu Suncadia Medicine Co., Ltd.	HRS-5765 Tablet	—	NOT YET RECRUITING	2026-12	NCT07551167
Viscofan	—	—	NOT YET RECRUITING	2026-12-31	NCT06956807
Eli Lilly	LY3971297	—	NOT YET RECRUITING	2027-08	NCT07547540
35Pharma Inc	HS235	—	NOT YET RECRUITING	2027-09	NCT07123779
Addpharma Inc.	AD-118, AD-1181	—	NOT YET RECRUITING	2026-05	NCT07476157
R3 Stem Cell	Amniotic and Umbilical Cord Tissue Procedure	—	NOT YET RECRUITING	2024-03-20	NCT03899298
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-9057	—	COMPLETED	2025-10-29	NCT06506994
Thryv Therapeutics, Inc.	THRV-1268	—	COMPLETED	2025-10-20	NCT07186946
AstraZeneca	AZD5462 film-coated tablet	—	COMPLETED	2025-06-25	NCT06989983
Novo Nordisk	NNC0537-1482	—	COMPLETED	2025-05-04	NCT06625307
Humanis Saglık Anonim Sirketi	Sacubitril and Valsartan-Test product	—	COMPLETED	2025-01-20	NCT06922253
ModernaTX, Inc.	mRNA-0184	—	COMPLETED	2024-12-17	NCT05659264
Bayer	Formulation 1	—	COMPLETED	2024-09-30	NCT06474208
scPharmaceuticals, Inc.	SCP-111	—	COMPLETED	2024-06-14	NCT06167707
Eli Lilly	LY3461767	—	COMPLETED	2024-05-09	NCT04840914
Novartis	XXB750	—	COMPLETED	2024-01-18	NCT05328752
Bayer	Finerenone (BAY94-8862): intervention A	—	COMPLETED	2023-07-28	NCT07116512
AstraZeneca	AZD3427	—	COMPLETED	2022-09-14	NCT04630067
Alleviant Medical, Inc.	—	—	COMPLETED	2022-08-22	NCT05501652
Cardurion Pharmaceuticals, Inc.	CRD-740	—	COMPLETED	2022-08-03	NCT05437094
Alleviant Medical, Inc.	—	—	COMPLETED	2022-03-10	NCT05133089
Pfizer	Prazosin HCl 2mg	—	COMPLETED	2022-02-15	NCT04967443
Chong Kun Dang Pharmaceutical	D113	—	COMPLETED	2022-01-18	NCT05089279
Bayer	Vericiguat (BAY1021189) - Intervention A	—	COMPLETED	2021-12-22	NCT05086952
Boryung Pharmaceutical Co., Ltd	BR1016C	—	COMPLETED	2021-12-18	NCT05102266
Boryung Pharmaceutical Co., Ltd	BR1016A	—	COMPLETED	2021-12-14	NCT05102903
AstraZeneca	Treatment A	—	COMPLETED	2021-09-03	NCT04798222
Alleviant Medical, Inc.	—	—	COMPLETED	2021-08-16	NCT04583527
SQ Innovation, Inc.	—	—	COMPLETED	2021-08-13	NCT04846816
AstraZeneca	AZD4831	—	COMPLETED	2021-03-11	NCT04232345
Bayer	Pecavaptan (BAY1753011)	—	COMPLETED	2021-01-22	NCT05599997
Triple-Gene, LLC	INXN-4001	—	COMPLETED	2020-03-04	NCT03409627
Cardior Pharmaceuticals GmbH	CDR132L	—	COMPLETED	2020-01-31	NCT04045405
BioVentrix	—	—	COMPLETED	2019-12	NCT02553785
Olatec Therapeutics LLC	dapansutrile capsules	—	COMPLETED	2019-11-21	NCT03534297
Bristol-Myers Squibb	BMS-986231	—	COMPLETED	2019-08-29	NCT03515980
Bristol-Myers Squibb	BMS-986231 Formulation A	—	COMPLETED	2019-07-29	NCT03891108
AstraZeneca	AZD9977	—	COMPLETED	2019-05-02	NCT03801967
AstraZeneca	Treatment A	—	COMPLETED	2019-04-16	NCT03804645
AstraZeneca	AZD9977	—	COMPLETED	2019-04-01	NCT03843060
Bristol-Myers Squibb	BMS-986231	—	COMPLETED	2018-10-22	NCT03332186
Bial - Portela C S.A.	BIA 5-1058	—	COMPLETED	2018-10-05	NCT03489005
Ventrix, Inc.	VentriGel	—	COMPLETED	2018-09-05	NCT02305602
Otsuka Pharmaceutical Co., Ltd.	OPC-61815 16mg	—	COMPLETED	2018-07-05	NCT03510663
Amgen	AMG 986	—	COMPLETED	2018-03-12	NCT03318809
Sarfez Pharmaceuticals, Inc.	Demadex 20mg Tablet	—	COMPLETED	2017-07-20	NCT03214874
GSK	—	—	COMPLETED	2017-02-22	NCT02135861
GSK	GSK2798745 Micronized API without SLS and hypermellose (Tablet A)	—	COMPLETED	2016-12	NCT02925546
Acorda Therapeutics	GGF2	—	COMPLETED	2016-05	NCT01944683
Arbor Pharmaceuticals, Inc.	BiDil XR	—	COMPLETED	2016-04	NCT02522208
Medtronic Cardiac Rhythm and Heart Failure	—	—	COMPLETED	2015-12	NCT01365234
Stealth BioTherapeutics Inc.	MTP-131	—	COMPLETED	2015-04	NCT02388464
Bayer	Vericiguat (BAY1021189)	—	COMPLETED	2015-01-22	NCT04722484
Bayer	Vericiguat (BAY1021189)	—	COMPLETED	2015-01-21	NCT04722562
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2014-09-16	NCT04881994
Bristol-Myers Squibb	CXL-1427 Ascending Dose	—	COMPLETED	2014-04	NCT02819271
CareLigo AB	—	—	COMPLETED	2013-12-18	NCT03655496
Harvest Technologies	—	—	COMPLETED	2013-08	NCT01299324
Cytokinetics	AMG 423	—	COMPLETED	2013-01	NCT01737866
Acorda Therapeutics	Glial growth factor 2/ Neuregulin 1β3	—	COMPLETED	2012-12	NCT01258387
Bayer	BAY94-8862 (1.25mg)	—	COMPLETED	2012-11-28	NCT01687920
Sorbent Therapeutics	CLP	—	COMPLETED	2012-09	NCT01598740
Trevena Inc.	TRV120027	—	COMPLETED	2012-05	NCT01444872
Bial - Portela C S.A.	BIA 5-1058	—	COMPLETED	2012-01	NCT02151994
Medispec	—	—	COMPLETED	2012-01	NCT01251185
Juventas Therapeutics, Inc.	ACRX-100	—	COMPLETED	2012-01	NCT01082094
Nile Therapeutics	Cenderitide	—	COMPLETED	2011-10	NCT01316432
GSK	—	—	COMPLETED	2011-08	NCT01277679
Bayer	Finerenone (BAY94-8862)	—	COMPLETED	2011-05-05	NCT04908436
Corimmun GmbH	COR-1	—	COMPLETED	2010-01	NCT01043146
Lantheus Medical Imaging	LMI 1195-101	—	COMPLETED	2009-11	NCT00891241
GSK	SK&F-105517-D 10 mg capsule	—	COMPLETED	2009-08-21	NCT00742508
Bial - Portela C S.A.	BIA-5-453	—	COMPLETED	2008-10	NCT03014375
Bial - Portela C S.A.	BIA 5-453	—	COMPLETED	2008-08-14	NCT03090568
Bial - Portela C S.A.	BIA 5-453	—	COMPLETED	2008-08-12	NCT03090724
AstraZeneca	AZD3427	—	TERMINATED	2025-08-21	NCT06611423
35Pharma Inc	HS135	—	TERMINATED	2025-07-29	NCT06581159
AstraZeneca	AZD5462	—	TERMINATED	2025-05-29	NCT06639087
Bayer	BAY2413555 Dose 1	—	TERMINATED	2023-03-31	NCT05532046
GSK	GSK3884464	—	TERMINATED	2022-08-05	NCT05044325
AstraZeneca	AZD9977	—	TERMINATED	2020-03-31	NCT03682497
Amgen	AMG 986 IV	—	TERMINATED	2019-04-18	NCT03276728
Bristol-Myers Squibb	BMS-986224	—	TERMINATED	2019-04-17	NCT03281122
Merck	MK-7145	—	TERMINATED	2014-12-17	NCT01558674
Medtronic BRC	—	—	TERMINATED	2014-05	NCT01509495
Salubris Biotherapeutics Inc	JK07	—	WITHDRAWN	2023-05-26	NCT05322616
AstraZeneca	AZD3427	—	WITHDRAWN	2022-08-02	NCT04890548
Sequana Medical N.V.	—	—	WITHDRAWN	2020-12-31	NCT03032211
Merck	—	—	WITHDRAWN	2016-03	NCT02364752
Stealth BioTherapeutics Inc.	MTP-131	—	WITHDRAWN	2015-09	NCT02388529
Ageless Regenerative Institute	—	—	WITHDRAWN	2014-12	NCT01502514
Debiopharm International SA	Istaroxime	—	WITHDRAWN	—	NCT00869115

Novel Drugs by Company (New molecular entities)

Roche 1 drug

ACTIVASE

ALTEPLASE

BLA 1987

LEXICON PHARMS INC 1 drug

INPEFA

SOTAGLIFLOZIN

NDA 2023

Reformulations (29 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.